GI & Endoscopy

St. Louis-based Barnes-Jewish Hospital named Matthew Mutch, MD, the Solon and Bettie Gershman Chair in Colon and Rectal Surgery.

A study presented at Digestive Disease Week 2017 examined plecanatide's safety and efficacy for irritable bowel syndrome with constipation.

Technavio analysts expect the colonoscopy device market to grow at a compound annual growth rate of 4.63 percent from 2017 to 2021.

Polyethylene glycol is better for bowel prep than sodium picosulfate plus magnesium citrate, Medscape reports.

Six hedge fund managers reduced their funds position in Allergan during the first quarter of fiscal year 2017, Reuters reports.

Here are four updates on GI companies from the past week.

John Dugan III, MD, is a gastroenterologist at Medical Clinic of Houston.

Synergy Pharmaceuticals presented data on patients' struggles with chronic idiopathic constipation at Digestive Disease Week 2017.

A study published in the International Journal of Colorectal Disease examined colorectal patients' first degree relatives' screening rates.

Analysts have refuted Citron Research's report on Exact Science’s Cologuard which stated the product was a "seriously inferior product and a disastrous business model." Despite the report causing Exact Science's stock to drop 8 percent, analysts recommend the stock, MarketWatch…